These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8318067

  • 1. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E, Dejager S, Chapman MJ.
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [Abstract] [Full Text] [Related]

  • 2. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ, Bruckert E.
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [Abstract] [Full Text] [Related]

  • 3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 4. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [Abstract] [Full Text] [Related]

  • 5. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 6. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.
    Dejager S, Bruckert E, Chapman MJ.
    J Lipid Res; 1993 Feb; 34(2):295-308. PubMed ID: 8429263
    [Abstract] [Full Text] [Related]

  • 7. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [Abstract] [Full Text] [Related]

  • 8. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 9. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 10. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 11. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [Abstract] [Full Text] [Related]

  • 12. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K, Dobiásová M, Nagyová A, Fábry R, Rauchová H, Dusinská M.
    Eur J Clin Pharmacol; 1998 Jun; 54(9-10):697-9. PubMed ID: 9923570
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G, Bruckert E.
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 15. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 17. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
    Millar JS, Anber V, Shepherd J, Packard CJ.
    Atherosclerosis; 1999 Aug 01; 145(2):253-60. PubMed ID: 10488950
    [Abstract] [Full Text] [Related]

  • 18. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul 01; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 19. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF.
    Am J Cardiol; 1995 Feb 15; 75(5):348-53. PubMed ID: 7856526
    [Abstract] [Full Text] [Related]

  • 20. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation.
    Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D.
    J Lipid Res; 1988 Apr 15; 29(4):442-58. PubMed ID: 3392462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.